Navigation Links
New Cancer Treatment Achieves First Mesothelioma Success

After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.

Nashville, Tenn. (Vocus) May 14, 2009 -- After standard treatments failed to stop or slow the progression of her cancer, the first mesothelioma patient treated with a new protocol has shown a highly favorable response. These early results are similar to the investigative protocol's success against several other very aggressive cancers.

The first mesothelioma patient is a woman in her late forties who was exposed to asbestos in childhood. When her cancer was diagnosed in 2008, it already had filled most of the chest space where her right lung had been. She received the approved treatments for the cancer. As is typical for mesothelioma, however, it continued to grow steadily. Realizing that the usual chemotherapy regimen is never able to stop this cancer, she visited NeoPlas Innovation's Nashville clinic and began the new outpatient treatment.

Two months later, CT scans showed that the cancer had stabilized, and the largest of the tumors actually had regressed significantly in size. Improvement in her clinical condition correlated with the findings. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results from one patient, so no conclusions can be drawn yet. Mesothelioma is so relentless and uniformly fatal, though, that being able to stop its growth and spread is very exciting. Most importantly, it's a major victory for this patient. It mirrors the success we're seeing for the great majority of our patients with other cancers, as well." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma and certain sarcomas. It can be considered for other patients on a case-by-case basis.

The new treatment is simply an "off-label" combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. In 1998 Dr. Jeffrey Rubins and colleagues in Minneapolis demonstrated that lovastatin had a significant effect against mesothelioma cells in laboratory cultures. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers' growth and spread in as few as eight weeks of treatment. In many cases, patients have experienced active regression of tumors.

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

NeoPlas Innovation's web site,, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100.

For an interview with Dr. Cantrell, call 615-371-8100.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
Related Image:
New Cancer Treatment Achieves First Mesothelioma Success
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... At Grand ... comfortable and convenient setting. , When you have dental problems, you need to turn ... and can effectively diagnose and treat your needs, a friendly dentist who counsels you ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... specializes in general dentistry out of Glen Ridge, NJ. He has both ... to achieve optimal mastication. He is also an expert in cosmetic dentistry. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ”Dying Words: The ... be released on December 1, 2015, to coincide with World AIDS Day. The multi-media ... journalist who covered the AIDS epidemic as he was dying of the disease. , ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... ... An inventor from Charlottesville, Va., is concerned about the need for peace and ... due to loud noises," she said, "so I decided that there needs to be ... radio waves and microwaves." , The baby BABY MUFF prevents loud noises, radio waves ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  IBA Molecular North America, Inc. (IBAMNA), ... radiopharmaceuticals, announced that as of January 1, 2016, it ... The decision to rebrand the company reflects a refined ... as its close relationship with Zevacor Molecular.  Both IBAMNA ... Science (IHS). Peter Burke , Vice ...
(Date:11/30/2015)... , November 30, 2015 North ... and is expected to grow at a CAGR of 7.6% from ... was valued at USD 135.6 million in 2014, and is expected ... --> According to the new Market Research Report "North ... non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis And ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology: